• The big news of the day was ViroPharma (VPHM). The company received a complete response from the FDA to treat acute attacks of hereditary angioedema using Cinryze. VPHM’s stock was down slightly, but analysts say it won’t hurt the company’s outlook. [WSJ]

• Another big day for Carl Icahn as he gets one board seat at Biogen (BIIB). [The Street]

• Takeda is pulling its marketing application in the EU for diabetes drug alogliptin. [Genetic Engineering & Biotechnology News]

• Despite reported adverse events earlier this year, Roche will be presenting data on ACTEMRA(R) (tocilizumab). [ClinicaSpace]

• Merck wins appeal in Vioxx lawsuit. [WSJ]

• Xanodyne gets new president and raises $38. [BizJournals]

• Alcon is hiring (in Singapore)!!!! [OSN SuperSite]

• Shares of Novavax (NVAX) soared today after the company announced an NIH contract to test its swine flu vaccine. [BizJournals]

• Finally, Somaxon says it has resubmitted its NDA for Silenor (doxepin) to treat insomnia. We were pretty rough on them a few weeks back…we’ll try to be nicer. [BusinessWire]

Anonymous Tip? Laid off? Contact us: hr AT iguanabio DOT com

Related Posts